MRI Compared to PET/CT for Staging and Treatment Response in Lymphoma

Not Applicable

• Conditions: Lymphoma

• Registration Number: NCT02733887
• Lead Sponsor: Guangxi Medical University

Brief Summary

The lymph nodes or masses,positron emission tomography/computed tomography (PET/CT) standardized uptake values(SUV) results, whole body magnetic resonance imaging(MRI) intravoxel incoherent motion(IVIM) sequence D, D\*, f values and MRI volumes of lymphoma patients were compared before and after the chemotherapy in this project prospectively to provide data for evaluating the dependency and differences of PET/CT and whole body MRI in lymphoma staging and therapeutic evaluation. Long-term therapeutic effect indexes obtained in follow-up visits of patients such as Overall Survival(OS), Progression Free Survival (PFS) etc. were used to evaluate the diagnostic sensitivity and differences of MRI and PET/CT. The research could provide a new method of nonionizing radiation iconography for physicians to give appropriate treatments and predict prognosis.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-02
• Study First Submitted: 2016-03-17
• Status Verified: 2016-04
• Study First Submitted QC: 2016-04-05
• Last Update Submitted: 2016-04-05
• Study First Posted: 2016-04-12
• Last Update Posted: 2016-04-12
• Primary Completion: 2017-06

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 66

Inclusion Criteria

• Lymphoma subtypes were diagnosed on the basis of tissue samples obtained by biopsy or surgery according to the criteria outlined in the current World Health Organization (WHO) classification of hematologic and lymphoid malignancies, by a reference pathologist.
• Patients who gave written informed consent were referred for DWI-MRI and 18F-FDG-PET/CT.
• Stable physical medical conditions (patients conscious and comfortable, scheduled for an elective diagnostic imaging).

Exclusion Criteria

• Pregnancy, general contraindications to MRI, and therapeutic interventions between DWI-MRI and 18F-FDG-PET/CT were used.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
18F-FDG uptake in lymphomas with PET/CT	Within 30 days prior to start of chemotherapy	Different 18F-FDG uptake values in lymphoma tissue (e.g. SUVmax, SUVmean, binding potential) will be measured and correlated with immunohistochemically determined somatostatin receptor status, lymphoma aggressiveness and tissue biomarkers
Agreement between DWI-MRI and 18F-FDG PET/CT at diagnosis	Within 30 days prior to start of chemotherapy	Region based agreement (%; kappa value) of DWI-MRI with 18F-FDG PET/CT at diagnosis.
Agreement between DWI-MRI and 18F-FDG PET/CT in follow-up examinations	2 weeks after the 4th cycle of chemotherapy	Region based agreement (%; kappa value) of DWI-MRI with 18F-FDG PET/CT after completion of chemotherapy for treatment response assessment

Secondary Outcome Measures

Name	Time	Method
Progression Free Survival	6 months
Overall Survival	12 months

Trial Locations

Locations (1)

Affiliated Tumor Hospital，Guangxi Medical University; 🇨🇳 Nanning, China